Pronunciation
(eye BAN droh nate)
Storage/Stability
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Adverse Reactions
Percentages vary based on frequency of administration (daily vs monthly). Unless specified, percentages are reported with oral use.
>10%:
Gastrointestinal: Dyspepsia (4% to 12%)
Neuromuscular & skeletal: Back pain (4% to 14%)
Respiratory: Upper respiratory tract infection (2% to 34%)
1% to 10%:
Cardiovascular: Hypertension (6% to 7%)
Central nervous system: Headache (3% to 7%), dizziness (1% to 4%), fatigue (3%), insomnia (1% to 2%), depression (2%)
Dermatologic: Skin rash (1% to 2%)
Gastrointestinal: Abdominal pain (5% to 8%), diarrhea (2% to 7%), nausea (4% to 5%), dental disease (4%), constipation (3% to 4%), vomiting (3%), gastritis (2%), gastroenteritis (3%)
Genitourinary: Urinary tract infection (2% to 6%), cystitis (3%)
Hypersensitivity: Acute phase reaction-like symptoms (IV: 10%; oral: 3% to 9%), hypersensitivity reaction (3%)
Infection: Influenza (4% to 8%)
Local: Injection site reaction (<2%)
Neuromuscular & skeletal: Limb pain (1% to 8%), arthralgia (4% to 9%), myalgia (1% to 6%), arthropathy (4%), weakness (4%), localized osteoarthritis (1% to 3%), muscle cramps (2%)
Respiratory: Bronchitis (3% to 10%), pneumonia (6%), nasopharyngitis (3% to 4%), flu-like symptoms (1% to 3%), pharyngitis (3%)
Postmarketing and/or case reports: Acute renal failure, anaphylactic shock, anaphylaxis, angioedema, bronchospasm, bullous dermatitis, erythema multiforme, exacerbation of asthma, femur fracture (diaphyseal or subtrochanteric), hypocalcemia, iritis, musculoskeletal pain (bone, joint, or muscle; incapacitating), ophthalmic inflammation, osteonecrosis (oro-facial sites including the external auditory canal), osteonecrosis of the jaw, prolonged Q-T interval on ECG (Bonilla 2014), scleritis, Stevens-Johnson syndrome, uveitis
–
